Cargando…

Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report

RATIONALE: Hepatic hemangioma is rarely discovered during the infantile period. Although most of the cases are asymptomatic, some of them may suffer life-threatening situations. In this regard, early detection is mandatory for preventing the ominous consequences that might be culminated from the dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Mu-Chieh, Liu, Hsi-Che, Yeung, Chun-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358341/
https://www.ncbi.nlm.nih.gov/pubmed/30681565
http://dx.doi.org/10.1097/MD.0000000000014078
_version_ 1783391981840367616
author Tsai, Mu-Chieh
Liu, Hsi-Che
Yeung, Chun-Yan
author_facet Tsai, Mu-Chieh
Liu, Hsi-Che
Yeung, Chun-Yan
author_sort Tsai, Mu-Chieh
collection PubMed
description RATIONALE: Hepatic hemangioma is rarely discovered during the infantile period. Although most of the cases are asymptomatic, some of them may suffer life-threatening situations. In this regard, early detection is mandatory for preventing the ominous consequences that might be culminated from the disease. PATIENT CONCERNS: A 2-month-14-day-old female infant was found incidentally to have multiple hepatic lesions during a newborn ultrasound screen. She was born smoothly at term after a non-eventful pregnancy course. Physical examination was completely normal and postnatal vital signs were stable. DIAGNOSIS: Infantile multiple hepatic hemangiomas. INTERVENTION: High-resolution ultrasound and abdominal computer tomogram were conducted to confirm the diagnosis. Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1.5 mg/kg per day and increased gradually to 2.5 mg/kg per day. No obvious adverse effects were noted during the treatment course. Rapid clinical improvement with decreasing size was observed by ultrasound 10 days after the treatment. Eventually, hepatic lesions totally disappeared 4.5 months later. Propranolol in dosage of 2.5 mg/kg per day was continued until 6 months after the initial prescription. OUTCOMES: A period of 11-month follow-up revealed no evidence of recurrence of hemangiomas. LESSONS: Early diagnosis and intervention are mandatory for infantile hepatic hemangiomas to prevent possible ominous consequences. Though the propranolol therapy protocol for the disease is still under developing, the current report strengthens the recommendation to use propranolol as the first-line medication for treating infantile hepatic hemangiomas.
format Online
Article
Text
id pubmed-6358341
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63583412019-02-15 Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report Tsai, Mu-Chieh Liu, Hsi-Che Yeung, Chun-Yan Medicine (Baltimore) Research Article RATIONALE: Hepatic hemangioma is rarely discovered during the infantile period. Although most of the cases are asymptomatic, some of them may suffer life-threatening situations. In this regard, early detection is mandatory for preventing the ominous consequences that might be culminated from the disease. PATIENT CONCERNS: A 2-month-14-day-old female infant was found incidentally to have multiple hepatic lesions during a newborn ultrasound screen. She was born smoothly at term after a non-eventful pregnancy course. Physical examination was completely normal and postnatal vital signs were stable. DIAGNOSIS: Infantile multiple hepatic hemangiomas. INTERVENTION: High-resolution ultrasound and abdominal computer tomogram were conducted to confirm the diagnosis. Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1.5 mg/kg per day and increased gradually to 2.5 mg/kg per day. No obvious adverse effects were noted during the treatment course. Rapid clinical improvement with decreasing size was observed by ultrasound 10 days after the treatment. Eventually, hepatic lesions totally disappeared 4.5 months later. Propranolol in dosage of 2.5 mg/kg per day was continued until 6 months after the initial prescription. OUTCOMES: A period of 11-month follow-up revealed no evidence of recurrence of hemangiomas. LESSONS: Early diagnosis and intervention are mandatory for infantile hepatic hemangiomas to prevent possible ominous consequences. Though the propranolol therapy protocol for the disease is still under developing, the current report strengthens the recommendation to use propranolol as the first-line medication for treating infantile hepatic hemangiomas. Wolters Kluwer Health 2019-01-25 /pmc/articles/PMC6358341/ /pubmed/30681565 http://dx.doi.org/10.1097/MD.0000000000014078 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Tsai, Mu-Chieh
Liu, Hsi-Che
Yeung, Chun-Yan
Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report
title Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report
title_full Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report
title_fullStr Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report
title_full_unstemmed Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report
title_short Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report
title_sort efficacy of infantile hepatic hemangioma with propranolol treatment: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358341/
https://www.ncbi.nlm.nih.gov/pubmed/30681565
http://dx.doi.org/10.1097/MD.0000000000014078
work_keys_str_mv AT tsaimuchieh efficacyofinfantilehepatichemangiomawithpropranololtreatmentacasereport
AT liuhsiche efficacyofinfantilehepatichemangiomawithpropranololtreatmentacasereport
AT yeungchunyan efficacyofinfantilehepatichemangiomawithpropranololtreatmentacasereport